Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Missed Doses of Atomoxetine vs OROS Methylphenidate in ADHD
NCT01127646Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 4 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Jun 2010; status: terminated.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01127646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127646.